Dermata Therapeutics, Inc.

Name: Dermata Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

DRMANasdaqCIK 1853816HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.0m, Q2 FY2026

Net income−$3.0m, Q2 FY2026

Dermata Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$k	903	1,135	1,601	2,009	2,401	2,192	1,281	618	504	527	384	213
Selling, general and administrative	$k	not reported	not reported	not reported	not reported	824	1,008	1,059	1,155	1,256	1,374	1,543	2,801
Operating income	$k	(1,812)	(2,220)	(3,204)	(2,884)	(3,226)	(3,200)	(2,340)	(1,773)	(1,761)	(1,900)	(1,926)	(3,014)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(1,719)	(2,134)	(3,134)	(2,829)	(3,173)	(3,151)	(2,304)	(1,701)	(1,692)	(1,862)	(1,848)	(2,967)
Diluted EPS	$ per share	not reported	not reported	(7.06)	(41.82)	(20.41)	not reported	(4.47)	(1.66)	(1.65)	not reported	(0.48)	(0.74)
Basic EPS	$ per share	(0.54)	not reported	(7.06)	(41.82)	(20.41)	not reported	(4.47)	(1.22)	(1.65)	not reported	(0.48)	(0.74)

Balance sheet

Cash and equivalents$4.4m, Q2 FY2026

Shareholders' equity$3.5m, Q2 FY2026

Dermata Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	6.6	not reported	not reported	not reported	not reported	3.2	9.7	6.5	4.7	7.5	6.9	4.4
Current assets	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	7.9	not reported	5.2
Total assets	$m	7.3	8.0	5.2	5.2	6.7	3.5	10.0	6.6	5.1	7.9	7.5	5.3
Current liabilities	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Total liabilities	$m	0.9	1.6	1.4	1.9	1.9	2.0	2.7	1.0	1.1	1.6	1.1	1.8
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	6.4	6.4	3.8	3.3	4.7	1.6	7.3	5.6	4.0	6.2	6.4	3.5

Cash flow

Operating cash flow−$2.4m, Q2 FY2026

Dermata Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,772)	(1,147)	(2,704)	(2,126)	(3,419)	(2,914)	(1,934)	(2,690)	(1,804)	(1,372)	(2,480)	(2,422)

Diluted shares (weighted)4.02m, Q2 FY2026

Dermata Therapeutics, Inc., shares, quarterly
Line item	Unit	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	444	67.7	155	515	1,027	1,026	3,859	4,022

Shares outstanding: 4.02m at Aug 10, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.